Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164924 | 0.81 | MAOB (0.54) | MAOBMAOAADORA2BMEN1ALDH1A1 | |
| SCHEMBL5761877 | 0.79 | TSHR (0.50) | MAOBMAOAADORA2BL3MBTL1MEN1 | |
| SCHEMBL10487747 | 0.78 | ALDH1A1 (0.37) | MAOBMAOAMEN1ALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL5763481 | 0.78 | TSHR (0.49) | MAOBMAOAADORA2BL3MBTL1MEN1 | |
| SCHEMBL31722071 | 0.76 | MAOB (0.46) | MAOBMAOAADORA2BPSMB5PSMB8 | |
| SCHEMBL4784331 | 0.76 | MAOB (0.46) | MAOBMAOAADORA2BPSMB5PSMB8 | |
| SCHEMBL7443073 | 0.76 | MAOB (0.46) | MAOBMAOAADORA2BPSMB5PSMB8 | |
| SCHEMBL13134177 | 0.75 | MAOB (0.45) | MAOBMAOAADORA2BMEN1ALDH1A1 | |
| SCHEMBL13134182 | 0.75 | MAOB (0.45) | MAOBMAOAADORA2BPSMB5PSMB8 | |
| SCHEMBL10765497 | 0.72 | IDO1 (0.50) | MAOBMAOAPSMB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | MAOB 2020/4885MAOA 2311/4885ADORA2B 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.